ASX Penny Stocks To Watch In September 2026

The Australian market is currently navigating mixed signals, with a weaker US session impacting technology and growth-sensitive sectors, while energy stocks find support from rising crude oil prices. Amid these fluctuations, penny stocks—though considered a niche area—still present intriguing opportunities for investors seeking growth in smaller or newer companies. When backed by strong financial health, these stocks can offer potential value and stability in an ever-evolving market landscape.

Below we spotlight a couple of our favorites from our exclusive screener.

Betmakers Technology Group (ASX:BET)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Betmakers Technology Group Ltd develops and provides software, data, and analytics products for the B2B wagering market across various regions including Australia, New Zealand, the United States, the United Kingdom, Europe, and internationally with a market cap of A$240.86 million.

Operations: The company's revenue is derived from two main segments: Global Tote, which generated A$50.68 million, and Global Betting Services, contributing A$41.93 million.

Market Cap: A$240.86M

Betmakers Technology Group Ltd, with a market cap of A$240.86 million, reported A$92.6 million in sales for the year ending June 2026, showing revenue growth from the previous year. Despite being unprofitable, Betmakers has reduced its net loss significantly and maintains a strong cash runway exceeding three years due to positive free cash flow. The company is debt-free and trading below its estimated fair value by 26.8%. Recently, Tabcorp Holdings Limited announced plans to acquire Betmakers for approximately A$270 million, potentially offering shareholders attractive returns pending necessary approvals and conditions.

• Get an in-depth perspective on Betmakers Technology Group's performance by reading our balance sheet health report here.
• Explore Betmakers Technology Group's analyst forecasts in our growth report.

EMVision Medical Devices (ASX:EMV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring in Australia, with a market cap of A$160.81 million.

Operations: The company generates revenue of A$8.36 million from its research and development efforts in medical device technology.

Market Cap: A$160.81M

EMVision Medical Devices Ltd, with a market cap of A$160.81 million, focuses on neurodiagnostic technology and reported A$8.85 million in revenue for the year ending June 2026, an increase from the previous year. Despite this growth, the company remains unprofitable with a net loss of A$8.32 million. Its management and board are experienced, but it faces challenges such as increasing debt-to-equity ratio and forecasted earnings decline over the next three years. However, EMVision maintains more cash than total debt and has sufficient short-term assets to cover liabilities, providing some financial stability amidst its ongoing development efforts.

• Jump into the full analysis health report here for a deeper understanding of EMVision Medical Devices.
• Evaluate EMVision Medical Devices' prospects by accessing our earnings growth report.

Temple & Webster Group (ASX:TPW)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Temple & Webster Group Ltd operates as an online retailer specializing in furniture, homewares, and home improvement products in Australia, with a market cap of A$511.64 million.

Operations: The company generates revenue of A$664.59 million from selling furniture, homewares, and home improvement products.

Market Cap: A$511.64M

Temple & Webster Group Ltd, with a market cap of A$511.64 million, reported A$664.59 million in sales for the year ending June 2026, showing revenue growth but a decline in net income to A$4.3 million from A$11.3 million the previous year. Despite having no debt and sufficient short-term assets to cover liabilities, its profit margins have decreased to 0.6% from 1.9%. The company is trading below estimated fair value and forecasts suggest earnings growth of over 30% annually; however, recent negative earnings growth poses challenges compared to industry trends despite high-quality past earnings and an experienced board and management team.

• Dive into the specifics of Temple & Webster Group here with our thorough balance sheet health report.
• Review our growth performance report to gain insights into Temple & Webster Group's future.

Make It Happen

• Navigate through the entire inventory of 394 ASX Penny Stocks here.
• Ready To Venture Into Other Investment Styles? The end of cancer? These 35 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com